View on Pubmed.gov 29907163 | View on doi.org 10.1186/s40425-...
Cytokine release syndrome.
- Cologne Interventional Immunology, University Hospital of Cologne, Cologne, Germany. shima@uk-koeln.de.
- Intensive Care Program, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. shima@uk-koeln.de.
- Center of Integrated Oncology Cologne-Bonn, University Hospital of Cologne, Cologne, Germany. shima@uk-koeln.de.
- Intensive Care in Hemato-Oncologic Patients (iCHOP), Cologne, Germany. shima@uk-koeln.de.
- Cologne Interventional Immunology, University Hospital of Cologne, Cologne, Germany.
- Intensive Care Program, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
- Center of Integrated Oncology Cologne-Bonn, University Hospital of Cologne, Cologne, Germany.
- Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
- Translational Cancer Immunology, Gene Centre, University of Munich, Munich, Germany.
- German Cancer Consortium (DKTK), Heidelberg, Germany.
- Comprehensive Cancer Center Munich (CCCM), Munich, Germany.
- Department of General, Visceral and Cancer Surgery, University Hospital of Cologne, Cologne, Germany.
- Department of Dermatology/Venereology, University Hospital of Cologne, Cologne, Germany.
- Intensive Care in Hemato-Oncologic Patients (iCHOP), Cologne, Germany.
Abstract
During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint inhibition, and T-cell engaging therapies like bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T cells have shown remarkable efficacy in clinical trials and some of these agents have already received regulatory approval. However, along with growing experience in the clinical application of these potent immunotherapeutic agents comes the increasing awareness of their inherent and potentially fatal adverse effects, most notably the cytokine release syndrome (CRS). This review provides a comprehensive overview of the mechanisms underlying CRS pathophysiology, risk factors, clinical presentation, differential diagnoses, and prognostic factors. In addition, based on the current evidence we give practical guidance to the management of the cytokine release syndrome.
References
J Clin Invest. 1996 Dec 15;98(12):2819-26
Cytokine. 2016 Sep;85:101-8
Dis Model Mech. 2015 Apr;8(4):337-50
Blood. 2014 Jul 10;124(2):188-95
Cited by 1641 citations (total)
Journal Article Review
Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?
Electronic publication date May 14, 2022
Pedro Castro [...] Maribel Diaz-Ricart et al.
Patients with COVID-19 present a wide spectrum of disease severity, from asymptomatic cases in the majority to serious disease leading...
Journal Article
Compassionate Use of Rectal Ozone (O) in Severe COVID-19 Pneumonia: a Case-Control Study.
Electronic publication date March 30, 2021
Marcos Edgar Fernández-Cuadros [...] Olga Susana Pérez-Moro et al.
Objectives
To evaluate effect of rectal ozone in severe COVID-19 pneumonia and to compare it to standard of care (SOC).
Material and...
Conflict of interest statement
MeSH
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •